Abstract
R33711, a new drug with presumed potent calcium-antagonistic property, was found to suppress the insulinotropic action of glucose und gliclazide but not that of theophylline. A 0.2 ..mu..M concentration of R33711 was sufficient to abolish glucose-induced insulin release. At this concentration, R33711 inhibited the net uptake of /sup 45/Ca/sup 2 +/ by isolated islets, whether in the absence or presence of either glucose or sulfonylurea. In the isolated islets, R33711 failed to affect the glucose-stimulated production of lactate, the rate of /sup 45/Ca/sup 2 +/ efflux, the inhibitory action of glucose upon such an efflux and its increase in response to theophylline. These data are compatible with the view that R33711 inhibits entry of Ca/sup 2 +/ into the B-cell and that integrity of such an inward cationic movement usually plays a permissive role in the maintenance of the Ca/sup 2 +/-dependent insulin secretory process.
Malaisse, W J;
Sener, A;
Devis, G;
Somers, G
[1]
- Brussels Univ. (Belgium). Lab. of Experimental Medicine
Citation Formats
Malaisse, W J, Sener, A, Devis, G, and Somers, G.
Calcium-antagonists and islet function. V. Effect of R33711.
Germany: N. p.,
1976.
Web.
Malaisse, W J, Sener, A, Devis, G, & Somers, G.
Calcium-antagonists and islet function. V. Effect of R33711.
Germany.
Malaisse, W J, Sener, A, Devis, G, and Somers, G.
1976.
"Calcium-antagonists and islet function. V. Effect of R33711."
Germany.
@misc{etde_7212884,
title = {Calcium-antagonists and islet function. V. Effect of R33711}
author = {Malaisse, W J, Sener, A, Devis, G, and Somers, G}
abstractNote = {R33711, a new drug with presumed potent calcium-antagonistic property, was found to suppress the insulinotropic action of glucose und gliclazide but not that of theophylline. A 0.2 ..mu..M concentration of R33711 was sufficient to abolish glucose-induced insulin release. At this concentration, R33711 inhibited the net uptake of /sup 45/Ca/sup 2 +/ by isolated islets, whether in the absence or presence of either glucose or sulfonylurea. In the isolated islets, R33711 failed to affect the glucose-stimulated production of lactate, the rate of /sup 45/Ca/sup 2 +/ efflux, the inhibitory action of glucose upon such an efflux and its increase in response to theophylline. These data are compatible with the view that R33711 inhibits entry of Ca/sup 2 +/ into the B-cell and that integrity of such an inward cationic movement usually plays a permissive role in the maintenance of the Ca/sup 2 +/-dependent insulin secretory process.}
journal = {Horm. Metab. Res.; (Germany, Federal Republic of)}
volume = {8:6}
journal type = {AC}
place = {Germany}
year = {1976}
month = {Nov}
}
title = {Calcium-antagonists and islet function. V. Effect of R33711}
author = {Malaisse, W J, Sener, A, Devis, G, and Somers, G}
abstractNote = {R33711, a new drug with presumed potent calcium-antagonistic property, was found to suppress the insulinotropic action of glucose und gliclazide but not that of theophylline. A 0.2 ..mu..M concentration of R33711 was sufficient to abolish glucose-induced insulin release. At this concentration, R33711 inhibited the net uptake of /sup 45/Ca/sup 2 +/ by isolated islets, whether in the absence or presence of either glucose or sulfonylurea. In the isolated islets, R33711 failed to affect the glucose-stimulated production of lactate, the rate of /sup 45/Ca/sup 2 +/ efflux, the inhibitory action of glucose upon such an efflux and its increase in response to theophylline. These data are compatible with the view that R33711 inhibits entry of Ca/sup 2 +/ into the B-cell and that integrity of such an inward cationic movement usually plays a permissive role in the maintenance of the Ca/sup 2 +/-dependent insulin secretory process.}
journal = {Horm. Metab. Res.; (Germany, Federal Republic of)}
volume = {8:6}
journal type = {AC}
place = {Germany}
year = {1976}
month = {Nov}
}